|
|
Prepublished online as a Blood First Edition Paper on March 13, 2003; DOI 10.1182/blood-2002-09-2975.
 Previous Article | Table of Contents | Next Article 
Blood, 1 July 2003, Vol. 102, No. 1, pp. 303-310
NEOPLASIA
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP
Thomas J. Sayers,
Alan D. Brooks,
Crystal Y. Koh,
Weihong Ma,
Naoko Seki,
Arati Raziuddin,
Bruce R. Blazar,
Xia Zhang,
Peter J. Elliott, and
William J. Murphy
From the Basic Sciences Program, SAIC-Frederick, the Laboratory of Molecular Immunoregulation, and the Laboratory of Experimental Immunology, National Cancer Institute—Center for Cancer Research, Frederick, MD; the Cancer Center and Department of Pediatrics, Division of BMT, University of Minnesota, Minneapolis; and Millennium Pharmaceuticals, Cambridge, MA.
Because of the pivotal role the proteasome plays in apoptosis, inhibitors of this enzyme, such as PS-341, provide a great opportunity for exploring synergy between proteasome inhibition and other apoptosis-inducing agents. Tumor necrosis factor—related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in tumor cells. In overnight assays, combinations of PS-341 and TRAIL were much more effective than either agent alone in promoting apoptosis of a murine myeloid leukemia, C1498, and a murine renal cancer, Renca. For C1498 cells, apoptosis sensitization by PS-341 affected neither the activity of nuclear factor  B (NF-B) nor the levels of most antiapoptotic proteins. However, reductions in the antiapoptotic protein c-FLIP in response to PS-341 were observed in both C1498 and Renca cells. Treatment of normal bone marrow mixed with C1498 tumor cells for 18 hours with a combination of PS-341 and TRAIL resulted in a specific depletion of the tumor cells. Upon transfer to irradiated syngeneic recipient mice, mixtures treated with the PS-341 plus TRAIL combination resulted in enhanced long-term tumor-free survival of mice. These data therefore support the targeting of apoptotic pathways in tumor cells, using combinations of agents such as PS-341 and TRAIL that interact synergistically to preferentially promote tumor cell apoptosis. (Blood. 2003;102:303-310)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Begley and A. Ribas
Targeted Therapies to Improve Tumor Immunotherapy
Clin. Cancer Res.,
July 15, 2008;
14(14):
4385 - 4391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Li, R. Li, J. R. Grandis, and D. E. Johnson
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells
Mol. Cancer Ther.,
June 1, 2008;
7(6):
1647 - 1655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Shanker, A. D. Brooks, C. A. Tristan, J. W. Wine, P. J. Elliott, H. Yagita, K. Takeda, M. J. Smyth, W. J. Murphy, and T. J. Sayers
Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody
J Natl Cancer Inst,
May 7, 2008;
100(9):
649 - 662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Baritaki, E. Suzuki, K. Umezawa, D. A. Spandidos, J. Berenson, T. R. Daniels, M. L. Penichet, A. R. Jazirehi, M. Palladino, and B. Bonavida
Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells
J. Immunol.,
May 1, 2008;
180(9):
6199 - 6210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kandasamy and A. S. Kraft
Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region
Mol. Cancer Ther.,
May 1, 2008;
7(5):
1091 - 1100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.-T. Liu, S. G. Agrawal, J. G. Gribben, H. Ye, M.-Q. Du, A. C. Newland, and L. Jia
Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL
Blood,
March 1, 2008;
111(5):
2797 - 2805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shi, G. J. Tricot, T. K. Garg, P. A. Malaviarachchi, S. M. Szmania, R. E. Kellum, B. Storrie, A. Mulder, J. D. Shaughnessy Jr, B. Barlogie, et al.
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma
Blood,
February 1, 2008;
111(3):
1309 - 1317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H.D. Hallett, E. Ames, M. Motarjemi, I. Barao, A. Shanker, D. L. Tamang, T. J. Sayers, D. Hudig, and W. J. Murphy
Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition
J. Immunol.,
January 1, 2008;
180(1):
163 - 170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Koschny, J. Sykora, H. Walczak, T. M. Ganten, T. L. Haas, M. R. Sprick, H. Holland, P. Ahnert, W. Krupp, J. Meixensberger, et al.
Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL
Clin. Cancer Res.,
November 1, 2007;
13(21):
6541 - 6542.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Smith, F. Jin, and I. Joshi
Bortezomib Sensitizes Non Hodgkin's Lymphoma Cells to Apoptosis Induced by Antibodies to Tumor Necrosis Factor Related Apoptosis-Inducing Ligand (TRAIL) Receptors TRAIL-R1 and TRAIL-R2
Clin. Cancer Res.,
September 15, 2007;
13(18):
5528s - 5534s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Miller, K. Ban, M. E. Dujka, D. J. McConkey, M. Munsell, M. Palladino, and J. Chandra
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells
Blood,
July 1, 2007;
110(1):
267 - 277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Koschny, H. Holland, J. Sykora, T. L. Haas, M. R. Sprick, T. M. Ganten, W. Krupp, M. Bauer, P. Ahnert, J. Meixensberger, et al.
Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis
Clin. Cancer Res.,
June 1, 2007;
13(11):
3403 - 3412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Liu, P. Yue, S. Chen, L. Hu, S. Lonial, F. R. Khuri, and S.-Y. Sun
The Proteasome Inhibitor PS-341 (Bortezomib) Up-Regulates DR5 Expression Leading to Induction of Apoptosis and Enhancement of TRAIL-Induced Apoptosis Despite Up-Regulation of c-FLIP and Survivin Expression in Human NSCLC Cells
Cancer Res.,
May 15, 2007;
67(10):
4981 - 4988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Li, X. Zhang, and A. F. Olumi
MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating c-Fos/c-Jun Heterodimers and Repressing c-FLIP(L)
Cancer Res.,
March 1, 2007;
67(5):
2247 - 2255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Aleo, C. J. Henderson, A. Fontanini, B. Solazzo, and C. Brancolini
Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis.
Cancer Res.,
September 15, 2006;
66(18):
9235 - 9244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Khanbolooki, S. T. Nawrocki, T. Arumugam, R. Andtbacka, M. S. Pino, R. Kurzrock, C. D. Logsdon, J. L. Abbruzzese, and D. J. McConkey
Nuclear factor-{kappa}B maintains TRAIL resistance in human pancreatic cancer cells.
Mol. Cancer Ther.,
September 1, 2006;
5(9):
2251 - 2260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lundqvist, S. I. Abrams, D. S. Schrump, G. Alvarez, D. Suffredini, M. Berg, and R. Childs
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Cancer Res.,
July 15, 2006;
66(14):
7317 - 7325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Khan, J. K. Stauffer, R. Williams, J. A. Hixon, R. Salcedo, E. Lincoln, T. C. Back, D. Powell, S. Lockett, A. C. Arnold, et al.
Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors
J. Immunol.,
May 15, 2006;
176(10):
6302 - 6312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Y. Schumacher, D. D. Vo, H. J. Garban, B. Comin-Anduix, S. K. Owens, V. B. Dissette, J. A. Glaspy, W. H. McBride, B. Bonavida, J. S. Economou, et al.
Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade).
J. Immunol.,
April 15, 2006;
176(8):
4757 - 4765.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Oyarzo, L. J. Medeiros, C. Atwell, M. Feretzaki, V. Leventaki, E. Drakos, H. M. Amin, and G. Z. Rassidakis
c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma
Blood,
March 15, 2006;
107(6):
2544 - 2547.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Vodanovic-Jankovic, P. Hari, P. Jacobs, R. Komorowski, and W. R. Drobyski
NF-{kappa}B as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145
Blood,
January 15, 2006;
107(2):
827 - 834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Zou, P. Yue, N. Lin, M. He, Z. Zhou, S. Lonial, F. R. Khuri, B. Wang, and S.-Y. Sun
Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells
Clin. Cancer Res.,
January 1, 2006;
12(1):
273 - 280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. BROOKS, T. RAMIREZ, U. TOH, J. ONKSEN, P. J. ELLIOTT, W. J. MURPHY, and T. J. SAYERS
The Proteasome Inhibitor Bortezomib (Velcade) Sensitizes Some Human Tumor Cells to Apo2L/TRAIL-Mediated Apoptosis
Ann. N.Y. Acad. Sci.,
November 1, 2005;
1059(1):
160 - 167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Sun, D. E. C. Wilkins, M. R. Anver, T. J. Sayers, A. Panoskaltsis-Mortari, B. R. Blazar, L. A. Welniak, and W. J. Murphy
Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity
Blood,
November 1, 2005;
106(9):
3293 - 3299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Fernandez, M. Verhaegen, T. P. Miller, J. L. Rush, P. Steiner, A. W. Opipari Jr., S. W. Lowe, and M. S. Soengas
Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic Implications
Cancer Res.,
July 15, 2005;
65(14):
6294 - 6304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Lashinger, K. Zhu, S. A. Williams, M. Shrader, C. P.N. Dinney, and D. J. McConkey
Bortezomib Abolishes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance via a p21-Dependent Mechanism in Human Bladder and Prostate Cancer Cells
Cancer Res.,
June 1, 2005;
65(11):
4902 - 4908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nencioni, F. Hua, C. P. Dillon, R. Yokoo, C. Scheiermann, M. H. Cardone, E. Barbieri, I. Rocco, A. Garuti, S. Wesselborg, et al.
Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis
Blood,
April 15, 2005;
105(8):
3255 - 3262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. McMahon, K. R. Gustafson, and C. J. Henrich
Molecular-Targeted Drug Screening at the NCI Center for Cancer Research
Am. Assoc. Cancer Res. Educ. Book,
April 1, 2005;
2005(1):
125 - 129.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Finnberg, J. J. Gruber, P. Fei, D. Rudolph, A. Bric, S.-H. Kim, T. F. Burns, H. Ajuha, R. Page, G. S. Wu, et al.
DR5 Knockout Mice Are Compromised in Radiation-Induced Apoptosis
Mol. Cell. Biol.,
March 1, 2005;
25(5):
2000 - 2013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nikrad, T. Johnson, H. Puthalalath, L. Coultas, J. Adams, and A. S. Kraft
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim
Mol. Cancer Ther.,
March 1, 2005;
4(3):
443 - 449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Papageorgiou, L. Lashinger, R. Millikan, H. B. Grossman, W. Benedict, C. P. N. Dinney, and D. J. McConkey
Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Interferon-Induced Apoptosis in Human Bladder Cancer Cells
Cancer Res.,
December 15, 2004;
64(24):
8973 - 8979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Blaney, M. Bernstein, K. Neville, J. Ginsberg, B. Kitchen, T. Horton, S. L. Berg, M. Krailo, and P. C. Adamson
Phase I Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study (ADVL0015)
J. Clin. Oncol.,
December 1, 2004;
22(23):
4804 - 4809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-Y. Wu, Y.-C. Chang, T.-L. Hsu, S.-L. Hsieh, and M.-Z. Lai
Sensitization of Cells to TRAIL-induced Apoptosis by Decoy Receptor 3
J. Biol. Chem.,
October 15, 2004;
279(42):
44211 - 44218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Sun, L. A. Welniak, A. Panoskaltsis-Mortari, M. J. O'Shaughnessy, H. Liu, I. Barao, W. Riordan, R. Sitcheran, C. Wysocki, J. S. Serody, et al.
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
PNAS,
May 25, 2004;
101(21):
8120 - 8125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Zheng, G. V. Georgakis, Y. Li, A. Bharti, D. McConkey, B. B. Aggarwal, and A. Younes
Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-{kappa}B Mutations or Activation of the CD30, CD40, and RANK Receptors
Clin. Cancer Res.,
May 1, 2004;
10(9):
3207 - 3215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Schmitz, H. Weyd, A. Krueger, S. Baumann, S. C. Fas, P. H. Krammer, and S. Kirchhoff
Resistance of Short Term Activated T Cells to CD95-Mediated Apoptosis Correlates with De Novo Protein Synthesis of c-FLIPshort
J. Immunol.,
February 15, 2004;
172(4):
2194 - 2200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Y. Koh, J. R. Ortaldo, B. R. Blazar, M. Bennett, and W. J. Murphy
NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade
Blood,
December 1, 2003;
102(12):
4067 - 4075.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
